20
Participants
Start Date
July 13, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
April 30, 2026
Placebo
Placebo
Spironolactone
"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
RECRUITING
National Institute on Drug Abuse, Baltimore
National Institute on Drug Abuse (NIDA)
NIH